This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Theodore Van Putten, MD; Philip R. A. May, MD

Arch Gen Psychiatry. 1978;35(9):1101-1107.

Abstract
• It is possible that some "postpsychotic depressions" may be a toxic effect of antipsychotic drugs. Out of a total of 94 schizophrenic patients, 28 developed a mild akinesia and 32 never developed extrapyramidal symptoms. Those who developed akinesia became less psychotic, but they also experienced a significant, although modest, increase in depression ratings. Successful treatment of the akinesia resulted in significant improvements in depression, somatic concern, anxiety, emotional withdrawal, blunted affect, and motor retardation on both physicians' and nurses' ratings. A high association between akinesia and both objectively rated and subjectively experienced sedative effect indicates that an "akinetic depression" is not likely if the patient does not look or feel drowsy. The 32 nonakinetic patients also became less psychotic, but not more depressed.

Author Affiliations
From the VA Hospital and the Department of Psychiatry, UCLA.

Footnotes
Accepted for publication April 10, 1978.

Reprint requests to VA Hospital, Brentwood, Wilshire and Sawtelle boulevards, Los Angeles, CA 90073 (Dr Van Putten).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Psychiatric Comorbidities and Schizophrenia
Buckley et al.
Schizophr Bull 2009;35:383-402.
ABSTRACT | FULL TEXT  

Atypical antipsychotics in bipolar disorder: the treatment of mania
Cookson
Adv. Psychiatr. Treat. 2008;14:330-338.
ABSTRACT | FULL TEXT  

Symptom domains of schizophrenia: the role of atypical antipsychotic agents
Burton
J Psychopharmacol 2006;20:6-19.
ABSTRACT  

Does Self-perceived Mood Predict More Variance in Cognitive Performance Than Clinician-Rated Symptoms in Schizophrenia?
Halari et al.
Schizophr Bull 2006;32:751-757.
ABSTRACT | FULL TEXT  

Subdomains Within the Negative Symptoms of Schizophrenia: Commentary
Kirkpatrick and Fischer
Schizophr Bull 2006;32:246-249.
FULL TEXT  

Open Forum: Effectiveness Versus Efficacy of Second-Generation Antipsychotics: Haloperidol Without Anticholinergics as a Comparator
Rosenheck
Psychiatr. Serv. 2005;56:85-92.
FULL TEXT  

Health Promotion in Persons with Schizophrenia: Atypical Medications
Beebe
J Am Psychiatr Nurses Assoc 2003;9:115-122.
ABSTRACT  

Differential Effect of Quetiapine on Depressive Symptoms in Patients with Partially Responsive Schizophrenia
Emsley et al.
J Psychopharmacol 2003;17:210-215.
ABSTRACT  

Suicide and schizophrenia
Siris
J Psychopharmacol 2001;15:127-135.
ABSTRACT  

Cognitive approach to depression and suicidal thinking in psychosis: I. Ontogeny of post-psychotic depression
BIRCHWOOD et al.
Br. J. Psychiatry 2000;177:516-528.
ABSTRACT | FULL TEXT  

Cognitive approach to depression and suicidal thinking in psychosis: 2. Testing the validity of a social ranking model
BIRCHWOOD et al.
Br. J. Psychiatry 2000;177:522-528.
ABSTRACT | FULL TEXT  

The symptom of depression in schizophrenia and its management
Mulholland and Cooper
Adv. Psychiatr. Treat. 2000;6:169-177.
FULL TEXT  

Depressive Signs and Symptoms in Schizophrenia: A Prospective Blinded Trial of Olanzapine and Haloperidol
Tollefson et al.
Arch Gen Psychiatry 1998;55:250-258.
ABSTRACT | FULL TEXT  

Pharmacotherapy of Impaired Affect in Recovering Schizophrenic Patients
Hogarty et al.
Arch Gen Psychiatry 1995;52:29-41.
ABSTRACT  

Maintenance Imipramine Therapy for Secondary Depression in Schizophrenia: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1994;51:109-115.
ABSTRACT  

A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten et al.
Arch Gen Psychiatry 1990;47:754-758.
ABSTRACT  

Antidepressants in 'Depressed' Schizophrenic Inpatients: A Controlled Trial
Kramer et al.
Arch Gen Psychiatry 1989;46:922-928.
ABSTRACT  

Adjunctive Imipramine in the Treatment of Postpsychotic Depression: A Controlled Trial
Siris et al.
Arch Gen Psychiatry 1987;44:533-539.
ABSTRACT  

Costs and Benefits of Two Doses of Fluphenazine
Marder et al.
Arch Gen Psychiatry 1984;41:1025-1029.
ABSTRACT  

Development and Prediction of Postpsychotic Depression in Neuroleptic-Treated Schizophrenics
Mandel et al.
Arch Gen Psychiatry 1982;39:197-203.
ABSTRACT  

Postpsychotic Depressive Symptoms in Hospitalized Schizophrenic Patients
Siris et al.
Arch Gen Psychiatry 1981;38:1122-1123.
ABSTRACT  

'Revealed' Depression and Drug Treatment for Schizophrenia
Knights and Hirsch
Arch Gen Psychiatry 1981;38:806-811.
ABSTRACT  

Fluphenazine and Social Therapy in the Aftercare of Schizophrenic Patients: Relapse Analyses of a Two-Year Controlled Study of Fluphenazine Decanoate and Fluphenazine Hydrochloride
Hogarty et al.
Arch Gen Psychiatry 1979;36:1283-1294.
ABSTRACT  

Predicting Drug-Free Improvement in Schizophrenic Psychosis
Marder et al.
Arch Gen Psychiatry 1979;36:1080-1085.
ABSTRACT  

Psychiatry
Freedman
JAMA 1979;241:1373-1375.
ABSTRACT